Protalex, Inc. Announces Dosing of First Patient in a Phase 1b Study of PRTX-100 in Patients With Active Rheumatoid Arthritis
Published: Aug 20, 2010
SUMMIT, N.J., Aug. 20, 2010 (GLOBE NEWSWIRE) -- Protalex, Inc. (OTCBB:PRTX), a clinical stage biopharmaceutical company engaged in developing a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, today announced the dosing of the first patient in a multicenter Phase 1b clinical study of PRTX-100 in adult patients with active Rheumatoid Arthritis (RA). The study is being conducted in South Africa.